[Comment] Nivolumab plus ipilimumab in hepatocellular carcinoma

Hepatocellular carcinoma is the third leading cause of cancer-related mortality worldwide and, unlike other cancer types, the incidence continues to rise.1 Before 2020, the first-line management of unresectable hepatocellular carcinoma was limited to the tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib. However, the treatment landscape has been dramatically reshaped by the introduction of combination immunotherapy, including STRIDE (single tremelimumab regular interval durvalumab),2 atezolizumab plus bevacizumab,3 camrelizumab plus rivoceranib,4 and sintilimab plus bevacizumab,5 all of which have shown significant improvement in overall survival versus sorafenib in randomised, phase 3 studies.